시장보고서
상품코드
1300105

세계의 특발성 폐섬유증 시장 : 약물 유형별, 투여 경로별, 유통 채널별, 지역별, 국가별 분석, 시장 인사이트, 예측

Global Idiopathic Pulmonary Fibrosis Market : Analysis By Drug Type, Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast

발행일: | 리서치사: Azoth Analytics | 페이지 정보: 영문 260 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 특발성 폐섬유증 시장 규모는 2022년 43억 9,000만 달러에서 2029년 말에는 106억 4,000만 달러에 달할 것으로 예상되며, 예측 기간인 2024년부터 2029년까지 연평균 46.3%의 성장률을 보일 것으로 예상됩니다.

이 보고서는 세계 특발성 폐섬유증 시장에 대해 조사했으며, 시장 규모와 예측, 지역 및 부문 분석, 주요 동향과 기회 등의 정보를 전해드립니다.

목차

제1장 시장 배경

  • 범위와 제품 전망
  • 주요 요약
  • 조사 방법

제2장 전략적 추천사항

  • 새로운 치료법 개발을 위한 연구개발 체제 강화
  • 치료 접근성 개선

제3장 세계의 특발성 폐섬유증 시장 : 실적과 예측

  • 특발성 폐섬유증 시장에 대한 거시경제 요인의 영향 분석
  • 가장 복잡한 IPF 증상
  • 특발성 폐섬유증 진단된 유병 증례
  • 파이프라인의 IPF 치료제 경쟁 상황
  • IPF에 의한 만성 기침
  • 특발성 폐섬유증 : 팩트 시트
  • IPF에 의한 만성 기침 병태생리학
  • IPF의 만성 기침 관련 병존질환
  • 세계의 특발성 폐섬유증 시장 : 대시보드
  • 세계의 특발성 폐섬유증 시장 : 시장 금액 평가(2018-2028년)
  • 세계의 특발성 폐섬유증 시장에 대한 COVID-19의 영향
  • 세계의 특발성 폐섬유증 시장 세분화 : 약제 유형별
  • 세계의 특발성 폐섬유증 시장 세분화 : 투여 경로별
  • 세계의 특발성 폐섬유증 시장 세분화 : 유통 채널별

제4장 세계의 특발성 폐섬유증 시장, 지역 분석

  • 연구 지역 범위

제5장 아메리카의 특발성 폐섬유증 시장 : 실적과 예측(2018-2028년)

  • 아메리카의 특발성 폐섬유증 시장 : 현황
  • 아메리카의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
  • 아메리카의 특발성 폐섬유증 시장 : 주요 요인
  • 아메리카의 특발성 폐섬유증 시장 세분화 : 약제 유형별
  • 아메리카의 특발성 폐섬유증 시장 세분화 : 투여 경로별
  • 아메리카의 특발성 폐섬유증 시장 세분화 : 유통 채널별
  • 아메리카의 특발성 폐섬유증 시장 세분화 : 국가별
    • 미국의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 캐나다의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 기타 아메리카의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)

제6장 유럽의 특발성 폐섬유증 시장 : 실적과 예측(2018-2028년)

  • 유럽의 특발성 폐섬유증 시장 : 현황
  • 유럽의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
  • 유럽의 특발성 폐섬유증 시장 : 주요 요인
  • 유럽의 특발성 폐섬유증 시장 세분화 : 약제 유형별
  • 유럽의 특발성 폐섬유증 시장 세분화 : 투여 경로별
  • 유럽의 특발성 폐섬유증 시장 세분화 : 유통 채널별
  • 유럽의 특발성 폐섬유증 시장 세분화 : 국가별
    • 프랑스의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 영국의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 이탈리아의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 스페인의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 독일의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 기타 유럽의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)

제7장 아시아태평양의 특발성 폐섬유증 시장 : 실적과 예측(2018-2028년)

  • 아시아태평양의 특발성 폐섬유증 시장 : 현황
  • 아시아태평양의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
  • 아시아태평양의 특발성 폐섬유증 시장 : 주요 요인
  • 아시아태평양의 특발성 폐섬유증 시장 세분화 : 약제 유형별
  • 아시아태평양의 특발성 폐섬유증 시장 세분화 : 투여 경로별
  • 아시아태평양의 특발성 폐섬유증 시장 세분화 : 유통 채널별
  • 아시아태평양의 특발성 폐섬유증 시장 세분화 : 국가별
    • 중국의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 일본의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 한국의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 인도의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
    • 기타 아시아태평양의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)

제8장 중동 및 아프리카의 특발성 폐섬유증 시장 : 실적과 예측(2018-2028년)

  • 중동 및 아프리카의 특발성 폐섬유증 시장 : 현황
  • 중동 및 아프리카의 특발성 폐섬유증 시장 : 시장 규모와 CAGR(2018-2028년)
  • 중동 및 아프리카의 특발성 폐섬유증 시장 : 주요 요인
  • 중동 및 아프리카의 특발성 폐섬유증 시장 세분화 : 약제 유형별
  • 중동 및 아프리카의 특발성 폐섬유증 시장 세분화 : 투여 경로별
  • 중동 및 아프리카의 특발성 폐섬유증 시장 세분화 : 유통 채널별

제9장 시장 역학

  • 세계의 특발성 폐섬유증 시장에 대한 시장 역학의 영향 평가
  • 성장 촉진요인
  • 성장 억제요인
  • 동향

제10장 업계 생태계 분석

  • 거시경제 요인 평가
  • Porter's Five Forces 모델

제11장 경쟁 포지셔닝

  • 기업의 제품 포지셔닝
  • 시장 포지션 매트릭스
  • 특발성 폐섬유증 시장의 시장 점유율 분석
  • 기업 개요
    • Boehringer Ingelheim
    • F. Hoffmann-La Roche AG
    • Cipla Ltd.
    • Shionogi & Co., Ltd.
    • Bristol-Myers Squibb Co.
    • United Therapeutics
    • FibroGen, Inc.
    • Pliant Therapeutics
    • Galecto Inc.
    • CSL Behring
ksm 23.07.10

Executive Summary

Azoth Analytics has released a research report titled "Idiopathic Pulmonary Fibrosis Market (2023 Edition)" which provides a complete analysis of the global Idiopathic Pulmonary Fibrosis industry in terms of market segmentation by Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Parenteral, Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 11 countries (United States, Canada, Mexico, United Kingdom, Germany, France, Italy, China, India, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

During the forecast period, 2024-2029, the Global Idiopathic Pulmonary Fibrosis market is expected to expand at a CAGR of 46.3%. The Global Idiopathic Pulmonary Fibrosis Market is expected to generate USD 10.64 billion by the end of 2029, up from USD 4.39 billion in 2022.

IPF is a life-threatening illness and is both progressive and incurable. Treatments can manage symptoms, limit disease progression, and improve quality of life. Pirfenidone and nintedanib are authorized IPF treatments that slow fibrosis. Severe instances may require lung transplants.

Although IPF is considered a rare disease, its incidence has increased over time. It is estimated that 13 to 20 people per 100,000 are affected globally. The prevalence is higher in older age categories, and the disease is diagnosed more frequently in people over 50. IPF affects both men and women, although men are slightly more susceptible. Ongoing research and clinical trials are investigating novel treatments and potential IPF therapies. Among these are antifibrotic agents, immunomodulatory drugs, and other novel therapeutic approaches that target different pathways implicated in the fibrotic process.

IPF patients need medical follow-ups. Work with interstitial lung disease specialists to create a specific treatment plan and support methods. IPF is characterized by a persistent dry cough, shortness of breath (especially during physical activity), exhaustion, and chest pain. These symptoms typically develop and worsen over time.

Scope of the Report:

  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).
  • The report presents the analysis of the Idiopathic Pulmonary Fibrosis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Pirfenidone, Nintedanib, Other drugs).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Route of Administration (Oral, Parenteral, Other ROA).
  • The report analyses the Idiopathic Pulmonary Fibrosis Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Boehringer Ingelheim, F. Hoffmann-La Roche AG, Cipla Ltd., Shionogi & Co., Ltd., Bristol-Myers Squibb Co., United Therapeutics, FibroGen, Inc., Pliant Therapeutics, Galecto Inc., CSL Behring

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

  • 2.1 Enhancing R&D operations for the development of novel treatments
  • 2.2 Improving access to treatment

3. Global Idiopathic Pulmonary Fibrosis Market: Historic and Forecast

  • 3.1 Impact Analysis of Macro Economic Factors on Idiopathic Pulmonary Fibrosis Market
  • 3.2 Most bothersome IPF symptom
  • 3.3 Idiopathic Pulmonary Fibrosis diagnosed prevalent cases
  • 3.4 Competitive Landscape for IPF Drugs in Pipeline
  • 3.5 Chronic Cough due to IPF
  • 3.6 Idiopathic Pulmonary Fibrosis: Fact Sheet
  • 3.7 Pathophysiology of Chronic Cough due to IPF
  • 3.8 Comorbidities Associated with Chronic Cough in IPF
  • 3.9 Global Idiopathic Pulmonary Fibrosis Market: Dashboard
  • 3.10 Global Idiopathic Pulmonary Fibrosis Market: Market Value Assessment, 2018-2028 (USD Million)
  • 3.11 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
  • 3.12 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 3.12.1 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type Type Overview
    • 3.12.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.12.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.12.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.13 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 3.13.1 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 3.13.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.13.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.13.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.14 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 3.14.1 Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 3.14.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies By Value, 2018H-2028F (USD Million & CAGR)
    • 3.14.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.14.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

4. Global Idiopathic Pulmonary Fibrosis Market, Regional Analysis

  • 4.1 Regional Coverage of the Study

5. Americas Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 5.1 Americas Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 5.2 Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 5.3 Americas Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 5.4 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 5.4.1 Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 5.4.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.5 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 5.5.1 Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 5.5.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.5.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.5.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.6 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 5.6.1 Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 5.6.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.6.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.6.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.7 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
    • 5.7.1 United States Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.1.1 United States Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 5.7.1.2 United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 5.7.1.3 United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 5.7.2 Canada Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.2.1 Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 5.7.2.2 Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 5.7.2.3 Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 5.7.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.3.1 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 5.7.3.2 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 5.7.3.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6. Europe Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 6.1 Europe Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 6.2 Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 6.3 Europe Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 6.4 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 6.4.1 Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 6.4.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.5 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 6.5.1 Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 6.5.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.5.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.5.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.6 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 6.6.1 Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 6.6.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.6.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.7 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
    • 6.7.1 France Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.1.1 France Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.1.2 France Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.1.3 France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.2 United Kingdom Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.2.1 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.2.2 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.2.3 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.3 Italy Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.3.1 Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.3.2 Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.3.3 Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.4 Spain Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.4.1 Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.4.2 Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.4.3 Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.5 Germany Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.5.1 Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.5.2 Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.5.3 Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 6.7.6 Rest of Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.6.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 6.7.6.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 6.7.6.3 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7. Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 7.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 7.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 7.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 7.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 7.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 7.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.5 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 7.5.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 7.5.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.5.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.5.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.6 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 7.6.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview
    • 7.6.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.6.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.6.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.7 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Country
    • 7.7.1 China Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.1.1 China Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.1.2 China Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.1.3 China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.2 Japan Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.1.1 Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.1.2 Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.1.3 Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.3 South Korea Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.3.1 South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.3.2 South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.3.3 South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.4 India Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.4.1 India Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.4.2 India Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.4.3 India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel
    • 7.7.5 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.5.1 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type
      • 7.7.5.2 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration
      • 7.7.5.3 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

8. Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

  • 8.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Snapshot
  • 8.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 8.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Key Factors
  • 8.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type
    • 8.4.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview
    • 8.4.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.5 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration
    • 8.5.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview
    • 8.5.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.5.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.5.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.6 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel
    • 8.6.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Distribution Channel: Overview
    • 8.6.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.6.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.6.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact Assessment of Market Dynamics on the Global Idiopathic Pulmonary Fibrosis Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Macro-Economic Factor Assessment
  • 10.2 Porter's Five Forces Model

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Position Matrix
  • 11.3 Market Share Analysis of Idiopathic Pulmonary Fibrosis Market
  • 11.4 Company Profiles
    • 11.4.1 Boehringer Ingelheim
    • 11.4.2 F. Hoffmann-La Roche AG
    • 11.4.3 Cipla Ltd.
    • 11.4.4 Shionogi & Co., Ltd.
    • 11.4.5 Bristol-Myers Squibb Co.
    • 11.4.6 United Therapeutics
    • 11.4.7 FibroGen, Inc.
    • 11.4.8 Pliant Therapeutics
    • 11.4.9 Galecto Inc.
    • 11.4.10 CSL Behring
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제